SIMPLIFY PATIENT ACCESS
WITH SILIQ SOLUTIONS™
2 ways to save on SILIQ
We are committed to helping your patients save on their SILIQ prescriptions.
Instant Savings Program
Eligible patients may pay as little as $0 per month with commercial insurance coverage for SILIQ.* Eligible patients without commercial insurance may pay as little as $50 per month.†
*Subject to a $15,000 maximum benefit for 24 months from first eligible date of program participation.
†If their commercial insurance does not cover SILIQ, or coverage is delayed or denied, they may pay as little as $50 per month for SILIQ until coverage is approved or up to 24 months from program initiation.
Uninsured patients are not eligible to participate in the Instant Savings Program. These offers are not valid for any person eligible for reimbursement of prescriptions, in whole or in part, by any federal, state or other governmental programs, including, but not limited to, Medicare (including Medicare Advantage and Part A, B and D Plans), Medicaid, TRICARE, Veterans Administration or Department of Defense health coverage, CHAMPUS, the Puerto Rico Government Health Insurance Plan, or any other federal or state health care programs. SILIQ Solutions™ Instant Savings cost support is determined by medication cost only. Amounts are not determined by costs associated with administration of the injection.
Eligibility Criteria, Terms, and Conditions for the SILIQ Solutions™ Instant Savings Program:
- If a commercially insured patient’s insurance covers SILIQ, he or she may pay as little as $0 per month for SILIQ, up to a maximum savings limit of $15,000 for 24 months from the patient’s first eligible date of program participation. Patient is responsible for all additional costs and expenses after savings program limit is reached.
- Participation in the SILIQ $50 per month program, for eligible patients whose commercial insurance does not cover SILIQ, will expire 24 months from program initiation. During this time, health care providers and patients are encouraged to work together to submit appeals to the patient’s health plan in order to obtain coverage to ensure continued treatment with SILIQ.
- These offers are valid for commercially insured patients being treated with SILIQ (brodalumab) injection, for subcutaneous use, for an approved indication, and are good for use only with a SILIQ prescription at the time the prescription is filled.
- Uninsured patients are not eligible to participate in the instant savings program.
- These offers are not valid for any person eligible for reimbursement of prescriptions, in whole or in part, by any federal, state or other governmental programs, including but not limited to Medicare (including Medicare Advantage and Part A, B and D Plans), Medicaid, TRICARE, Veterans Administration or Department of Defense health coverage, CHAMPUS, the Puerto Rico Government Health Insurance Plan, or any other federal or state health care programs.
- Eligible patients may not seek reimbursement for all or any part of the benefit received through these offers and are responsible for making any required reports of use of these offers to any insurer or other third party who pays any part of the prescription filled.
- These offers are good only in the USA, including Puerto Rico, at pharmacies enrolled in the SILIQ REMS Program. These offers are not valid in states where otherwise prohibited, taxed, or otherwise restricted.
- Patient must be 18 years of age or older to redeem these offers for him or herself or for a minor.
- Each membership period is 24 months long and covers up to 50 injections or 26 fills of SILIQ.
- This savings program is only good for use with SILIQ. No other purchase necessary.
- This savings program is not health insurance.
- This savings program membership is not transferable. The selling, purchasing, trading, or counterfeiting of this savings program membership information is prohibited by law. Void if reproduced.
- These offers are not valid with other offers. This savings program membership information has no cash value. No cash back.
- Ortho Dermatologics’ affiliated entities reserve the right to rescind, revoke, terminate, or amend these offers at any time, without notice.
- The patient understands and agrees to comply with the terms and conditions of these offers.
Patient Assistance Program
Ortho Dermatologics is committed to ensuring effective options are available to combat the devastating effects of moderate to severe plaque psoriasis. So, if you have a patient with financial needs, SILIQ Solutions is here to help. Simply fill out the application on the Bausch Health Patient Assistance Website and have your patient do the same.
To be eligible for the SILIQ Patient Assistance Program (PAP), your patients must meet all program eligibility requirements on the Bausch Health Patient Assistance Website.
If you have any questions, please call the number below
Get SILIQ certified
It’s simple. Enrolling through the REMS portal takes just a few minutes.
INDICATION
SILIQ® injection is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.
IMPORTANT SAFETY INFORMATION
WARNING: SUICIDAL IDEATION AND BEHAVIOR
Suicidal ideation and behavior, including completed suicides, have occurred in patients treated with SILIQ. Prior to prescribing SILIQ, weigh the potential risks and benefits in patients with a history of depression and/or suicidal ideation or behavior. Patients with new or worsening suicidal ideation and behavior should be referred to a mental health professional, as appropriate. Advise patients and caregivers to seek medical attention for manifestations of suicidal ideation or behavior, new onset or worsening depression, anxiety, or other mood changes [see Warnings and Precautions (5.1) in the full Prescribing Information].
Because of the observed suicidal behavior in subjects treated with SILIQ, SILIQ is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the SILIQ REMS Program [see Warnings and Precautions (5.2) in the full Prescribing Information].
Contraindications Do not use SILIQ in patients with Crohn's disease because SILIQ may cause worsening of disease; or in patients with clinically significant hypersensitivity to brodalumab or to any of the excipients in SILIQ or components of the container.
SILIQ Risk Evaluation and Mitigation Strategy (REMS) Program SILIQ is available only through a restricted program called the SILIQ REMS because of observed suicidal ideation and behavior in patients treated with SILIQ. Before prescribing SILIQ, prescribers must be certified with the program, have each patient sign a Patient-Prescriber Agreement Form, and provide the patient a Wallet Card describing symptoms requiring immediate medical evaluation. Pharmacies must be certified and only dispense to patients authorized to receive SILIQ. More information is available at SILIQREMS.com or by calling the SILIQ REMS Program Call Center at 855-511-6135855-511-6135.
Hypersensitivity Reactions Serious hypersensitivity reactions, including anaphylaxis requiring hospitalization, have been reported. If a serious hypersensitivity reaction occurs, immediately discontinue SILIQ and initiate appropriate therapy.
Infections SILIQ may increase the risk of infections. Serious infections and fungal infections were observed at a higher rate in patients treated with SILIQ than placebo-treated patients in clinical trials, including one case of cryptococcal meningitis that led to discontinuation of therapy.
Consider risks and benefits prior to prescribing SILIQ in patients with a chronic infection or history of recurrent infection.
Instruct patients to seek treatment if signs or symptoms of a chronic or acute infection occur.
Risk for Latent Tuberculosis (TB) Reactivation Evaluate patients for TB prior to initiating treatment with SILIQ and do not treat patients with active TB. Initiate treatment for latent TB prior to starting SILIQ and consider anti-TB therapy prior to initiation in patients with history of latent TB if adequate treatment cannot be confirmed. Monitor closely for symptoms of active TB during and after treatment.
Eczematous Eruptions Postmarketing cases of severe eczematous eruptions, including atopic dermatitis-like eruptions, have been reported. The onset of eczematous eruptions was variable, ranging from days to months after the first dose of SILIQ. Some cases of severe eczematous eruptions resulted in hospitalization. Treatment may need to be discontinued to resolve the eczematous eruption. Some patients with limited psoriasis treatment options were successfully treated for eczema while continuing SILIQ.
Crohn’s Disease In clinical trials, which excluded Crohn’s patients, one SILIQ patient was withdrawn after developing Crohn’s disease. Discontinue SILIQ if a patient develops Crohn’s disease.
Immunizations Avoid use of live vaccines in patients treated with SILIQ.
Adverse Reactions The most commonly reported adverse reactions in clinical trials were arthralgia, headache, fatigue, diarrhea, oropharyngeal pain, nausea, myalgia, injection site reactions, influenza, neutropenia, and tinea infections.
To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health at 1-800-321-4576 or the FDA at 1-800-FDA-1088, or visit www.fda.gov/medwatch.
INDICATION
SILIQ® injection is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.
Click here for full Prescribing Information, including Boxed Warning about suicidal ideation and behavior.
Indication and Important Safety Information
Indication and Important Safety Information
SILIQ® injection is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to ...
IMPORTANT SAFETY INFORMATION
WARNING: SUICIDAL IDEATION AND BEHAVIOR
Suicidal ideation and behavior, including completed suicides, have occurred in patients treated with SILIQ. Prior to prescribing SILIQ, weigh the potential risks and benefits in patients with a history of depression and/or ...
WARNING: SUICIDAL IDEATION AND BEHAVIOR
Suicidal ideation and behavior, including completed suicides, have occurred in patients treated with SILIQ. Prior to prescribing SILIQ, weigh the potential risks and benefits in patients with a history of depression and/or ...